Home › NDC Lookup › RxCUI directory › RxCUI 402091

Gefitinib 250 MG Oral Tablet [Iressa] — RxCUI 402091

RxNorm drug concept · Semantic branded drug
RxCUI 402091 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI402091
Official nameGefitinib 250 MG Oral Tablet [Iressa]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asIressa 250 MG Oral Tablet
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Gefitinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Gefitinib only works in lung cancers that carry specific EGFR gene mutations — specifically an exon 19 deletion or an exon 21 (L858R) mutation. Without those mutations, the drug ha...
  • Why do I need a genetic test before starting gefitinib?
  • Good news — you can take gefitinib with or without food, whichever works best for your routine. There are no specific foods listed as a concern, but some medicines that affect your...
  • Can I take gefitinib with food, and are there any foods or drinks I should avoid?
📖 Read our full Gefitinib guide →

🕸️ Concept Web — How Gefitinib 250 MG Oral Tablet [Iressa] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Gefitinib 250 MG Oral Tablet [Iressa] RxCUI 402091

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Gefitinib 328134
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Iressa 281883
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Gefitinib Oral Tablet 378629
    • Gefitinib Oral Product 1156708
    • Gefitinib Pill 1156709
    • Gefitinib Oral Tablet [Iressa] 402435
    • Iressa Oral Product 1176762
    • Iressa Pill 1176763
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Gefitinib 250 MG Oral Tablet SCD · 349472
  • Gefitinib 250 MG SCDC · 358777
  • Gefitinib Oral Tablet SCDF · 378629
  • Gefitinib Oral Product SCDG · 1156708
  • Gefitinib Pill SCDG · 1156709

Brand-Name Concepts

  • Gefitinib 250 MG [Iressa] SBDC · 576099
  • Gefitinib Oral Tablet [Iressa] SBDF · 402435
  • Iressa Oral Product SBDG · 1176762
  • Iressa Pill SBDG · 1176763
  • Iressa BN · 281883

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 402091 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00310-0482-30 30 TABLET, COATED in 1 BOTTLE (0310-0482-30) IRESSA AstraZeneca Pharmaceuticals LP 2015-07-13
Observed labelers: AstraZeneca Pharmaceuticals LP (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.